DDInter690 DDInter1014
A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages.
Lacosamide is an antiepileptic drug used to treat seizures. As a chiral functionalized amino acid, it works by blocking slowly inactivating components of voltage-gated sodium currents. Lacosamide exhibits a stereoselective mode of interaction with sodium channels. Lacosamide was first approved by the European Commission in August 2008 and was later approved by the FDA in October 2008. It was granted approval by Health Canada in September 2010.
Ethanol {u} (Compound) binds {v} (Gene) CYP2B6
CYP2B6 {u} (Gene) is bound by {v} (Compound) Lidocaine
Lidocaine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lacosamide
Ethanol {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} (Compound) resembles {v} (Compound) Lacosamide
Ethanol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lacosamide
Ethanol {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Phenelzine
Phenelzine {u} (Compound) resembles {v} (Compound) Lacosamide
Ethanol {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is associated with {v} (Disease) epilepsy syndrome
epilepsy syndrome {u} (Disease) is treated by {v} (Compound) Lacosamide
Ethanol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dolasetron
Dolasetron {u} may lead to a major life threatening interaction when taken with {v} Lacosamide
Ethanol (Compound) binds CYP2B6 (Gene) and CYP2B6 (Gene) is bound by Lidocaine (Compound) and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Lacosamide
Ethanol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Bortezomib (Compound) and Bortezomib (Compound) resembles Lacosamide (Compound)
Ethanol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Lacosamide
Ethanol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Phenelzine (Compound) and Phenelzine (Compound) resembles Lacosamide (Compound)
Ethanol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is associated with epilepsy syndrome (Disease) and epilepsy syndrome (Disease) is treated by Lacosamide (Compound)
Ethanol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dolasetron (Compound) and Dolasetron may lead to a major life threatening interaction when taken with Lacosamide